期刊文献+

沙利度胺加联合化疗治疗恶性浆细胞疾病的疗效和不良反应 被引量:10

The outcome and side-effects in patients with malignant plasma cell diseases treated with thalidomide combined with combination chemotherapy
原文传递
导出
摘要 目的初步评价沙利度胺加联合化疗对恶性浆细胞疾病患者的疗效和毒副作用。方法17例多发性骨髓瘤和5例浆细胞白血病患者,采用沙利度胺联合VAD(T-VAD方案)或CED(T-CED方案)或MP(T-MP方案)治疗2~4疗程,评价其疗效和毒副作用。结果21例可评价疗效的患者,6例(28.6%)获得完全缓解(CR),10例(47.6%)获得部分缓解(PR),总有效率(CR+PR)为76.2%,中位生存时间为48个月。所有患者共接受了86个疗程的治疗,最常见的不良反应为指端麻木感(40.9%),便秘(40.9%),嗜睡(36.4%),水肿(27.3%),未出现一例深静脉血栓(DVT)。结论沙利度胺加联合化疗治疗恶性浆细胞疾病疗效好,毒副作用轻微,易于耐受。 Objective To explore the outcome and side-effects in patients with malignant plasma cell diseases treated with thalidomide and combined chemotherapy. Methods 17 patients with multiple myeloma (MM) and 5 patients with plasma cell leukemia (PCL) were treated with the combination of thalidomide and VAD(T-VAD regimen) or CED(T-CED regimen) or MP(T-MP regimen) chemotherapy. Response to treatment and side-effects were evaluated after two or four cycles of treatment. Results On an intention-to-treat basis, 16 of the 21 patients (76.2 %) responded to treatment. Six patients (28.6 %) achieved complete remission(CR) and 10 (47.6 %) achieved partial remission(PR). The median survival time was 48 months. In the entire group of patients, a total of 86 cycles of therapy was given. Major toxicities consisted of numbness (40.9 %), consti- pation (40.9 %), somnolence (36.4 %) and edema (27.3 %), and no one patient experienced deep vein thrombosis (DVT). Conclusions Thalidomide combined combination chemotherapy is an effective and relatively well-tolerated treatment for patients with malignant plasma cell diseases.
出处 《白血病.淋巴瘤》 CAS 2006年第1期16-19,共4页 Journal of Leukemia & Lymphoma
关键词 沙利度胺 联合化疗 恶性浆细胞疾病 Malignantplasmacelldiseases Thalidomide Combinedwith combination chemotherapy
  • 相关文献

参考文献15

  • 1Singhai S,Mehta J,Desikan R,et al.Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med,1999,341(21):1565-1571.
  • 2Weber D,Rankin K,Gavino M,et al.Thalidomide alone or with dexamethasone for previous untreated multiple myeloma[J].J Clin Oncol,2003,21(1):16-19.
  • 3Zervas K,Dimopoulos M A,Hatzicharissi E,et al.Primary treatment of multiple myeloma with thalidomide,vincristine,liposomal doxorubicin and dexamethasone (T-VAD doxil):a phase Ⅱ multicenter study[J].Ann Oncol,2004,15(1):134-138.
  • 4Schutt P,Ebeling P,Buttkereit U,et al.Thalidomide in combination with vincristine,epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma[J].Eur J Haematol,2005,74(1):40-46.
  • 5肖志坚,秦铁军.反应停加联合化疗治疗浆细胞白血病一例[J].中华血液学杂志,2002,23(6):336-336. 被引量:2
  • 6Durie B G M,Salmon S E.A clinical stage system for multiple myeloma[J].Cancer,1975,36(3):842-845.
  • 7Greipp P R,Miguel J S,Durie B G M,et al.International staging system for multiple myeloma[J].J Clin Oncol,2005,23(15):3412-3420.
  • 8Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.Myeloma Subcommittee of the EBMT [J].European Group for Blood and Marrow Transplant.Br J Haematol,1998,102(5):1115-1123.
  • 9Myeloma Trialists' Collaborative Group.Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6,633 patients from 27 randomized trials [J].J Clin Oncol,1998,16(12):3832-3842.
  • 10麦玉洁,李睿,邹德慧,王亚非,赵耀中,杨仁池,王建祥,肖志坚,韩明哲,钱林生,邱录贵.206例多发性骨髓瘤患者不同方案疗效分析[J].中华血液学杂志,2005,26(4):193-196. 被引量:37

二级参考文献8

  • 1Alexanian R, Haut A, Khan AU,et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA, 1969,208:1680-1685.
  • 2Rajkumar SV, Gerta MA, Kyle RA,et al. Current therapy for multiple meloma. Mayo Clin Proc, 2002, 77: 813-822.
  • 3Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6,633 patients from 27 randomized trials. J Clin Oncol, 1998,16:3832-3842.
  • 4Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple meloma:an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol, 2001,113:1020-1034.
  • 5Singhal S, Mehta J. Novel therapy in multiple myeloma. Int J Hematol, 2003,77:226-231.
  • 6Weber DM. Newly diagnosed multiple myeloma. Curr Treat Options Oncol, 2002,3:235-245.
  • 7Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopietic stem-cell rescue for multiple myeloma. N Engl J Med ,2003,348:1875-1883.
  • 8Stadtmauer EA. Multiple myeloma, 2004-one or two transplants?N Engl J Med, 2003,349:2551-2553.

共引文献37

同被引文献62

  • 1麦玉洁,邱录贵,李睿,靳风艳,白洁,万长春,王建祥,季林祥,肖志坚,钱林生.432例多发性骨髓瘤临床分析[J].白血病.淋巴瘤,2004,13(4):198-201. 被引量:27
  • 2熊文杰,杜新,游伟文,卓家才,汪明春.不同剂量沙利度胺联合化疗治疗多发性骨髓瘤24例观察[J].海南医学,2007,18(6):112-113. 被引量:3
  • 3林志翔,戴禄寿,郑良成,戴益琛,李天德.沙利度胺治疗强直性脊柱炎疗效观察[J].实用医学杂志,2007,23(13):2079-2080. 被引量:12
  • 4Barlogie B,Smith L,Alexanian R.Effective treatment of advanced multiple myeloma refractory to alkylating agents[J].N Engl J Med,1984,310(21):1353-1355
  • 5Singhal S,Mehta J,Deslkan R,et al,Antitumor activity of thalidomide in refractorymultiple myeloma.N Engl J Med,1999,341(18):1565-1571
  • 6Rajkumar SV,GetzMA,LacyMQ,et al.Thalidomide as initial theropy for early stage myeloma[J].Leukemia,2003,17(4):775-779
  • 7Rajkumar SV,Rosiol L,Hussein M,et al.Multicenter,randomized,double-blind,placebo controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma[J].J Clin Oncol,2008,26(13):2171-2177
  • 8Deng L,DingW,Granstein RD.Thalidomide inhibits tumor necrosis factor-αproduction and antigen presentation by Langerhans cells[J].J Invest Dermatol,2003,121(5):1060-1065
  • 9Weber D,Rankin K,Gavino M,et al.Thalidomide alone or with dexamethasone for previous untreated multiple myeloma[J].J Clin Oncol,2003,21(1):16-19
  • 10Zangari M,Anaissie E,Barlogie B,et al.Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy[J].Blood,2001,98(5):1614-1615

引证文献10

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部